Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Status Active, not recruiting

Clinical Trial Summary

This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Clinical Trial Description

PRIMARY OBJECTIVE: -To establish the response rate of pembrolizumab in metastatic cutaneous squamous cell carcinoma. SECONDARY OBJECTIVES: -To determine the 6-month progression-free survival and 1 year overall survival of metastatic cutaneous squamous cell carcinoma of the skin (cSCC) treated with pembrolizumab. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 8-12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02964559
Study type	Interventional
Source	Emory University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 27, 2017
Completion date	February 27, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02978625` - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Phase 2
Completed	`NCT03353077` - Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)	N/A
Active, not recruiting	`NCT03944941` - Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer	Phase 2
Recruiting	`NCT05269381` - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Phase 1
Completed	`NCT01807546` - Oral Rigosertib for Squamous Cell Carcinoma	Phase 2
Active, not recruiting	`NCT04234113` - Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors	Phase 1
Recruiting	`NCT03822988` - ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS
Recruiting	`NCT06223659` - EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers	Phase 2
Active, not recruiting	`NCT00954226` - Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	Phase 1
Completed	`NCT03108131` - Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors	Phase 2